PELyon has adopted home based working for all of its employees since March, without affecting our activities. We will continue to favor this way of working, in order to follow government recommendations.
In an effort to preserve biodiversity, PELyon is proud to become the sponsor of a beehive, located in Beaujolais (north of Lyon).
By sponsoring a beehive, we allow 80,000 bees to wake up to recreate biodiversity in the surrounding spaces.
This project reflects PELyon’s societal commitment to a sustainable development approach. The bee is also a beautiful symbol of team spirit!
Thank you to Pollinium for giving us the opportunity to participate, on our scale, in the protection of the planet (www.pollinium.fr).
# biodiversity #csr
PELyon is proud to be part of the new European Network to Advance Best Practices & Technologies on Medication Adherence (ENABLE). It has just been funded by the European Union’s Cooperation in Science and Technology (COST). Awareness of healthcare professionals on the availability and implementation of adherence enhancing technology is limited and there is a lack of collaboration between stakeholders. This affects not only patients and healthcare professionals, but also manufacturers of technology (mostly SMEs) in their innovation capacity and competitiveness.
To address these challenges, ENABLE aims (amongst others):
1. to establish multidisciplinary medication adherence expertise centers in each country,
2. review novel adherence enhancing technologies,
3. organize training schools,
4. offer short-term fellowships for early career investigators,
5. organize conferences.
Presentation of PELyonPELyon conducts a broad range of research projects, with emphasis on pharmacoepidemiological studies, burden/cost of illness, adherence and Comparative Effectiveness Research.
PELyon consists of Medical Doctors, Epidemiologists, Project Managers, Data Managers and Statisticians, who combine their skills and experience to address current health-related issues.
PELyon aims at helping decision-makers (health authorities, biomedical industries, and healthcare settings) by offering tools that will enable them to choose between different therapeutic strategies or public health programmes.